Government Contracts For Biodefense: The Benefits and Risks. Robert V. House, PhD, FATS, Senior Vice President of Government Contracts at Ology Bioservices shares his thoughts on the benefits of Government Contracting in [...]
CEPI awards up to US$43.6 million to Public Health Vaccines, LLC. for development of a single-dose Nipah virus vaccine candidate Public Health Vaccine, LLC. will partner with Crozet Biopharma to develop the Nipah [...]
Blue Water Vaccines, Developing Universal Flu Vaccine, to Partner With Ology Bioservices Inc. PRESS RELEASE UPDATED: AUG 7, 2019 CINCINNATI, August 7, 2019 (Newswire.com) - Blue Water Vaccines, a Cincinnati-based biotechnology startup, [...]
Tomic MT, Espinoza Y, Martinez Z, et al. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins 2019, 11(4), 208; https://doi.org/10.3390/toxins11040208. Read More > [...]
Ology Bioservices Wins Two Department of Defense Awards Totaling More Than $135 Million ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of [...]
Ology Bioservices Appoints Vaccines and Biologics Manufacturing Industry Veteran, Brandon Brega, as Chief Operating Officer ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today the appointment [...]
Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua.
The NANO-ADM (Advanced Development and Manufacturing) facility, as it is known, will expand Nanotherapeutics’ core competencies in the development and cGMP manufacture of preclinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.
Tomic MT, Espinoza Y, Martinez Z, et al. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins 2019, 11(4), 208; https://doi.org/10.3390/toxins11040208.
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894.